Lexaria Bioscience Granted First European Patent for DehydraTECH Technology

October 21, 2020 6:15 AM

New patent includes method of treatment claims for a broad range of disease conditions including use of: cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer's and Parkinson's cannabinoids to treat metabolic disorders and substance abuse and addictions nicotine to treat tobacco dependence/addiction and neurological diseases NSAIDs to treat a host of conditions involving...

Read more

Novālent Welcomes Frank Sciortino as Director of Distributor Partnerships

October 20, 2020 2:45 PM

GREENSBORO, NC / ACCESSWIRE / October 20, 2020 / Novālent Biotech, Inc (‘Novālent'), a US biotechnology engineering firm, brings Frank Sciortino to its leadership team. As director of distributor partnerships, Mr. Sciortino brings 30 years of experience to his role responsible for building positive distributor relationships focused on mutual profit and growth. "Frank is a terrific addition to our team," explains Kevin...

Read more

Havn Life Sciences Signs Agreement to Supply Psychedelic Compounds for use in Research and Development to Revive Therapeutics

October 20, 2020 8:00 AM

Havn Life will export naturally derived psilocybin to the United States for use in IND-enabling studies and future clinical trials under FDA guidelines VANCOUVER, BC / ACCESSWIRE / October 20, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds...

Read more

Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration

October 20, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company") is pleased to announce that the Company has received initial In-Vitro study results from its collaboration with Syracuse University showing that Pritumumab ("PTB") successfully blocked viral entry into cells. Based on these results, PTB and will be advanced to laboratory-based animal...

Read more

Tetra Bio-Pharma Announces Positive Results in Animal Studies for Treatment of Hyperinflammatory Lung Injury

October 20, 2020 7:30 AM

Reduced the levels of key inflammatory cytokine markers Reduced fibrosis when the lung tissue was analyzed Reduced the effects of fibrosis-associated inflammatory pathways OTTAWA, ON / ACCESSWIRE / October 20, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, announced the results of an experimental study of...

Read more

Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S.

October 19, 2020 7:30 AM

TORONTO, ON / ACCESSWIRE / October 19, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. The Phase 2/3 study protocol has previously been approved by Health Canada. The company has begun the...

Read more

XPhyto Announces Update on Contract Drug Delivery Programs

October 19, 2020 3:05 AM

VANCOUVER, BC / ACCESSWIRE / October 19, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company"), a next-generation bioscience company, is pleased to announce an update on its third-party contract development programs. Over the past 12 months, XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has developed an oral disintegrating film...

Read more

Clyraguard Personal Protection Spray Now Available on Amazon.com for Consumers Nationwide

October 14, 2020 9:00 AM

BioLargo Subsidiary Clyra Medical Technologies Joins Forces With Powerplay Retail to Ensure Broad Availability of Revolutionary Product to Safeguard Against Airborne Viruses WESTMINSTER, CA / ACCESSWIRE / October 14, 2020 / Just in time for Amazon Prime Day, BioLargo, Inc. (OTCQB:BLGO), developer of sustainable life science technologies, today announced that Clyraguard, the personal disinfectant and germicidal spray that safely and easily...

Read more

Hancock Jaffe to Begin CoreoGraft First-in-Human Study

October 14, 2020 8:30 AM

First Two Surgeries Scheduled to Take Place by End of October IRVINE, CA / ACCESSWIRE / October 14, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the first two surgeries for its CoreoGraft first-in-human study are scheduled to take place by the end of October. Hancock Jaffe will provide an update on the first two patients once the...

Read more

Vitro Biopharma Announces Changes in SEC Registration

October 13, 2020 2:05 PM

GOLDEN, CO / ACCESSWIRE / October 13, 2020 / Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma announced the revocation of its SEC registration for Vitro Diagnostics, Inc while also announcing its plans for re-registration with the SEC. As noted in our prior releases, the Company is actively engaged in the process of regaining full compliance with SEC reporting requirements involving current ongoing annual financial audits for...

Read more

Havn Life Applies for Licence to Produce and Sell Psilocybin

October 13, 2020 8:00 AM

The Controlled Drugs and Substances Dealer's Licence will allow Havn Life to supply naturally-derived psilocybin globally to universities, clinical researchers and companies VANCOUVER, BC / ACCESSWIRE / October 13, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized...

Read more

Dyadic Updates Market on COVID-19 Initiatives

October 12, 2020 8:30 AM

C1 Expression of SARS-CoV-2 Monoclonal Antibody AchievedTen On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different CollaboratorsRecord Expression Level of C1 SARS-CoV-2 RBD Antigen (3 g/l in 5 days)Non-Exclusive Technology Usage Agreement with Epygen Biotech of IndiaJUPITER, FL / ACCESSWIRE / October 12, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global...

Read more

Marizyme Announces European DuraGraft(R) Registry Results Presented at the European Association for Cardio-Thoracic Surgery (EACTS) 34th Annual Virtual Meeting

October 9, 2020 5:45 PM

JUPITER, FL / ACCESSWIRE / October 9, 2020 / Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB:MRZM) is a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications. Today, Marizyme announced that results from its European DuraGraft Registry were presented on October 8, 2020 at the EACTS Annual Meeting. The...

Read more

Omnicanna Health Solutions, Inc. appoints Greta Gaines as President

October 9, 2020 9:30 AM

President Greta Gaines's first action as President is launching the Omnicanna's licensed real time negotiating industrial hemp eCommerce Website; www.ihemp.omnicanna.com RALEIGH, NC / ACCESSWIRE / October 9, 2020 / Omnicanna Health Solutions, Inc. (OTC PINK:ENDO), a U.S. Company specializing in hemp formulation-based health and wellness solutions, is pleased to announce the appointment of Greta Gaines as President, while launching its...

Read more

Hancock Jaffe Engages Syntactx for VenoValve U.S. Pivotal Trial

October 8, 2020 8:30 AM

Syntactx to provide CRO Services IRVINE, CA / ACCESSWIRE / October 8, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has engaged Syntactx LLC to assist Hancock Jaffe with the VenoValve U.S. pivotal trial. Syntactx will work with Hancock Jaffe in several key areas including strategy, clinical operations, regulatory affairs, and safety,...

Read more

Milestone Scientific to Present at MicroCap Rodeo Best Ideas Bowl on October 13th

October 7, 2020 11:30 AM

ROSELAND, NJ / ACCESSWIRE / October 7, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, today announced that it will be presenting at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th - 16th, 2020. Leonard Osser, Interim Chief Executive Officer, is scheduled to present on Tuesday, October 13th at 2:30...

Read more

ABMC to Distribute Co-Diagnostics Inc. EUA Issued Logix Smart(TM) Covid-19 Test

October 7, 2020 10:25 AM

KINDERHOOK, NY / ACCESSWIRE / October 7, 2020 / American Bio Medica Corporation (OTC PINK:ABMC) today announced they have signed a distribution agreement with Co-Diagnostics, Inc. (CODX) granting ABMC the right to market and sell the Logix Smart Covid-19 tests in the United States on a non-exclusive basis. The test operates using a single step RT-PCR process in lower respiratory tract fluid samples such as bronchoalveolar lavage, sputum,...

Read more

Hancock Jaffe Laboratories, Inc. Announces Pricing of $5.1 Million Registered Direct Offering Priced at the Market

October 7, 2020 8:30 AM

IRVINE, CA / ACCESSWIRE / October 7, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a registered direct offering of $5.1 million of its common stock and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and one warrant to purchase one share of common...

Read more

Optec Surpasses Previous Quarter's Income & Revenue by Over 600% for Period Ending September 30, 2020

October 7, 2020 8:00 AM

CARLSBAD, CA / ACCESSWIRE / October 7, 2020 / OPTEC International, Inc (OTC PINK:OPTI) today announced the company surpassed the financial income projections for the Quarter ending September 30, 2020. Interim (unaudited) financial overview can be found at these links: https://www.otcmarkets.com/stock/OPTI/news https://optecintl.com/investors/news/ In summary, the Company surpassed its $4,000,000 projection for this quarter and, in...

Read more

Tetra Bio-Pharma Unveils its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio

October 7, 2020 8:00 AM

DIN submission to be completed in Q4 2020 OTTAWA, ON / ACCESSWIRE / October 7, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide an update on its commercial strategy to bring innovative therapies to patients suffering from chemotherapy induced nausea and vomiting (CINV). Tetra will be...

Read more